Promising Developments in Biogen’s IgAN Treatments Drive Buy Rating

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Biogen, boosting the price target to $194.00.

Andrew Fein has given his Buy rating due to a combination of factors related to Biogen’s promising developments in the treatment of IgA nephropathy (IgAN) and primary membranous nephropathy. The advancement of felzartamab to the registrational stage in Phase 3 studies is a significant milestone, as it targets CD38, which is believed to more effectively deplete plasma cells and mitigate IgA production. This approach is particularly promising given the historical challenges with other immunological treatments like anti-CD20, which have not been as effective.
Furthermore, early data from felzartamab shows significant reductions in proteinuria without notable safety concerns, which is crucial for its potential approval and adoption as a standard of care. The sustained clinical benefits observed in Phase 2, including a 50% reduction in proteinuria and stabilization of renal function, underscore the drug’s potential efficacy. These factors, combined with the evolving landscape of IgAN treatments and the potential for felzartamab to meet key clinical endpoints, support Fein’s positive outlook and Buy rating for Biogen.

In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $175.00 price target.